The GLP-1 Revolution: How Weight-Loss Drugs Are Rewriting Metabolic Medicine
Eli Lilly's Zepbound and Novo Nordisk's Ozempic have done more than reshape bodies — they've reshaped an entire industry. We examine the science, the investment thesis, and what comes next.